The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon Stonehouse in the news release.
Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.
MediWound priced an underwritten public offering of 4.4 million shares at $5 apiece.
Bayer's takeover of Monsanto is expected to receive extra scrutiny out of fears the deal could prove detrimental for European farmers.
North Korea uses certain measures and tactics to evade UN sanctions - here are five of the eight.
Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.
Patent lawyers are intrigued and competitors will likely challenge, but the move to transfer ownership of the patent to the Saint Regis Mohawk tribe could cause other companies to try a similar tack.
Amgen sets to offer a competitor to Roche's Avastin.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.